What is ABVC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.03B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ABVC?

P/E (TTM) is n/a and 52-week range is $0.71 to $3.33 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ABVC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ABVC?

The company profile lists revenue (TTM) near $793K, net income (TTM) near $-180M, EPS (TTM) near $-0.32 when available from the market-data feed. Figures are informational and may lag live markets.

Where is ABVC Biopharma Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Fremont, California, US, 26M shares outstanding, ISIN US00091F3047 when available from company profile and filing metadata.

ABVC Biopharma Inc

$ABVC

Health Care · Biotechnology

IR Run Scenarios

$1.00

+2.04%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 19 full-time employees. The company went IPO on 2004-11-09. The firm is focused on the development of new drugs and medical devices, all of which are derived from plants. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1702, ABV-1703, ABV-1501, and ABV-1701. The firm is developing and researching ABV-1504, a botanical reuptake inhibitor that targets norepinephrine. ABV-1505 to treat attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1702 to treat Myelodysplastic syndromes. The company has developed an indication for pancreatic cancer from maitake extract, named ABV-1703. ABV-1501 for the treatment of Triple Negative Breast Cancer. ABV-1701 Vitargus for the treatment of Retinal Detachment or Vitreous Hemorrhage. ABV-1519 for the treatment of Non-Small Cell Lung Cancer.

Employees

Website

abvcpharma.com/

IPO

2004-11-09

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)